title: Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection.
abstract: BACKGROUND
  Invasive fungal infections, especially aspergillosis, are a major problem in patients who undergo aggressive therapy for haematological malignancies. Presently, the standard therapy for demonstrated aspergillar infection is voriconazole. Because the morbidity and the mortality of proven aspergillar infection is relatively high, empirical and preemptive approaches have been explored.
  
  
  RESULTS
  Empirical therapy is effective at the cost of overtreatment in a significant number of patients. This can be reduced through the preemptive approach; however, its equivalence in terms of successful therapy and mortality should be studied further and, optimally, in prospective controlled clinical trials.
authors.affiliation: Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, 1, rue Héger-Bordet, 1000, Bruxelles, Belgium.
authors.forename: Jean
authors.initials: J
authors.lastname: Klastersky
authors.forename: Marianne
authors.initials: M
authors.lastname: Paesmans
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000276:immunology; D001228:Aspergillosis / Q000188:drug therapy* / Q000209:etiology; D005334:Fever / Q000188:drug therapy / Q000209:etiology; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D000970:Antineoplastic Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole